What is the equity of MannKind this year?
MannKind has equity of -246.17 M USD this year.
MannKind Equity 2024
MannKind Equity
-246.17 M USD
Ticker
MNKD
ISIN
US56400P7069
WKN
A2DMZL
In 2024, MannKind's equity was -246.17 M USD, a -1.73% increase from the -250.5 M USD equity in the previous year.
MannKind Aktienanalyse
What does MannKind do?
MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing MannKind's Equity
MannKind's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding MannKind's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating MannKind's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
MannKind's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in MannKind’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about MannKind stock
What was the equity of MannKind compared to the previous year?
The equity of MannKind has increased/decreased by -1.73% decreased compared to the previous year.
What impact does a high equity have on investors of MannKind?
A high equity is advantageous for investors of MannKind as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of MannKind?
A low equity can be a risk for investors of MannKind, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of MannKind affect the company?
An increase in equity of MannKind can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of MannKind affect the company?
A reduction in equity of MannKind can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of MannKind?
Some factors that can affect the equity of MannKind include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of MannKind so important for investors?
The equity of MannKind is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can MannKind take to change the equity?
To change equity, MannKind can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does MannKind pay?
Over the past 12 months, MannKind paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MannKind is expected to pay a dividend of 0 USD.
What is the dividend yield of MannKind?
The current dividend yield of MannKind is .
When does MannKind pay dividends?
MannKind pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MannKind?
MannKind paid dividends every year for the past 0 years.
What is the dividend of MannKind?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MannKind located?
MannKind is assigned to the 'Health' sector.
Wann musste ich die Aktien von MannKind kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MannKind from 8/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did MannKind pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of MannKind in the year 2023?
In the year 2023, MannKind distributed 0 USD as dividends.
In which currency does MannKind pay out the dividend?
The dividends of MannKind are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MannKind stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MannKind
Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
